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Abstract To clarify the role of p53 in 22 hepatitis C virus
(HCV)-infected hepatocellular carcinomas (HCCs), we com-
pared the gene expression pro¢les of HCCs with wild-type
p53 (wt-p53) (n=17) and those with mutant-type p53 (mt-
p53) (n=5) by oligonucleotide microarray analysis. Among 83
p53-related genes identi¢ed by a supervised learning method, 25
were underexpressed, and 58 were overexpressed in mt-p53
HCCs compared with wt-p53 HCCs. With a computer search,
we identi¢ed consensus p53-binding sequences in the 3-kb region
upstream of the translation initiation site in 59 of the 83 genes,
suggesting that the in vivo p53-associated transcription system is
very complicated. These data will provide additional insights
into p53-related pathogenesis in HCV-infected HCC.
- 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Expression of the p53 gene is a major marker for the genetic
changes that occur in oncogenesis [1^4]. In particular, the p53
protein in£uences the transcription of many cellular genes by
binding to DNA in a sequence-speci¢c manner, resulting in
inhibition of cell growth and invasion. Conversely, p53 mu-
tants, which have been identi¢ed in a number of di¡erent
human cancers, fail to bind to the consensus DNA binding
site, resulting in a loss of tumor suppressor activity. Much
research has been devoted to identifying genes and proteins
involved in p53 abnormalities [4]. More recently, several in
vitro studies with DNA chip technology have identi¢ed gene
expression patterns associated with p53 status [5^7]. However,
most of these studies have used cultured cells. Whether the
patterns observed in cultured cells re£ect those in human tis-
sues remains unknown.
As in many cancers, abnormalities in the p53 gene occur
during the carcinogenesis and progression of hepatocellular
carcinoma (HCC) [8]. However, it remains unclear how the
HCC phenotype is in£uenced by p53. We have characterized
several subgroups of human HCC with DNA chip technology
[9^11]. In the present study, we investigated the gene expres-
sion pro¢le of human HCC with respect to p53 status with
DNA microarrays. A role of p53 abnormality has been docu-
mented in hepatitis B virus-related HCC [12] but not in hep-
atitis C virus (HCV)-related HCC. Therefore, we focused on
p53 abnormalities in HCV-related HCC. We identi¢ed a set of
genes that are di¡erentially expressed between HCCs with
wild-type p53 (wt-p53) and those with mutant-type p53 (mt-
p53).
2. Materials and methods
2.1. Patients
Twenty-two patients who underwent surgical treatment for HCC at
Yamaguchi University Hospital between May 1997 and August 2000
were enrolled in this study. None of them underwent chemotherapy
prior to surgery. Written informed consent was obtained from all
patients before surgery. The study protocol was approved by the In-
stitutional Review Board for Human Use at Yamaguchi University
School of Medicine. A histopathologic diagnosis of HCC was made
for all patients after surgery. All patients were positive for HCV anti-
body and were negative for hepatitis B virus surface antigen expres-
sion. Tumors were categorized on the basis of the International Union
against Cancer TNM Classi¢cation [13] (Table 1).
2.2. Sample preparation
We divided all tumor specimens resected from each patient into two
portions immediately after resection. One was ¢xed in 10% formalin
and embedded in para⁄n. The other was frozen in liquid nitrogen and
stored at 380‡C until oligonucleotide array analysis and cDNA se-
quencing.
2.3. cDNA sequencing of p53
RNA extraction and reverse transcription were performed as de-
scribed previously [14]. We ampli¢ed a 722-bp fragment (exons 5^9)
from p53 cDNA by polymerase chain reaction (PCR) with primers
5P-GTTTCCGTCTGGGCTTCTTGCA-3P (exon 4) and 5P-CAAG-
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GCCTCATTCAGCTCTC-3P (exon 10) as reported by Sjogren et al.
[14]. The sequence of the PCR products was determined by dye ter-
minator-based DNA sequencing as described elsewhere.
2.4. Immunohistologic evaluation of p53 nuclear accumulation
We used immunohistochemistry to evaluate the nuclear accumula-
tion of p53 in ¢ve wt-p53 tumors and ¢ve mt-p53 tumors of the 22
HCC samples subjected to oligonucleotide array analysis. Sections of
4 Wm thick were depara⁄nized in xylene and progressively rehydrated
in decreasing concentrations of alcohol. Subsequently, the sections
were treated with the EnVision1+ System (Dako, Kyoto, Japan)
and DO-7 antibody (Novacastra Laboratories, Tokyo, Japan) for
p53 staining as described previously [15]. We considered specimens
to be positive for nuclear staining when more than 10% of the p53
reactivity was localized within nuclei. Two investigators judged the
samples independently with no other knowledge of the cases, and
reproducibility was con¢rmed.
2.5. Gene expression analysis by high-density oligonucleotide array
We analyzed the levels of expression of approximately 6000 genes
by high-density oligonucleotide array (HuGeneFL Array, A¡ymetrix,
Santa Clara, CA, USA) as described previously [9^11]. Raw data for
15 of the 22 samples are available at http://surgery2.med.yamaguchi-u.
ac.jp/research/DNAchip/ [10].
2.6. Gene selection by supervised learning method
We performed gene selection by a supervised learning method com-
bined with random permutation tests as described previously [9,11].
Brie£y, we ¢rst selected genes that showed an average di¡erence of
s 20 arbitrary units (according to A¡ymetrix) in all 22 HCV-related
HCC samples. Among approximately 6000 genes, this ¢ltering re-
sulted in the selection of 2168 genes. Among the selected genes, we
used the Fisher ratio (Fisher criterion) to evaluate gene expression
di¡erences between wt-p53 tumors and mt-p53 tumors and ranked
the selected genes in order of decreasing magnitude of Fisher ratio
[9,11]. To decide how many genes should be considered, we used a
random permutation test as described previously [9,11]. The random
permutation of sample labels was repeated 1000 times. The Fisher
ratios generated from the actual data were then assigned P values
on the basis of the distribution of Fisher ratios from randomized
data. From the distribution of these Fisher ratios, the 83 genes with
Fisher ratios of s 2.12 were determined to have statistically signi¢-
cant (P6 0.01) di¡erences in expression between wt-p53 tumors and
mt-p53 tumors (Tables 2 and 3).
2.7. Identi¢cation of consensus p53 binding sequence by computer
It is generally accepted that wt-p53-induced genes contain a con-
sensus binding site consisting of two copies of a 10-bp motif (5P-
PuPuPuC(A/T)(T/A)GPyPyPy-3P) separated by 0^13 bp, whereas wt-
p53-repressed genes do not [16,17]. Our present study focused on
exons 5^9 of the p53 cDNA, which contain the DNA binding domain.
Mutation of this region disrupts transcriptional activity of wt-p53. It
is possible that genes upregulated in a wt-p53 tumor in our series are
regulated directly by wt-p53 at the level of transcription. To clarify
this possibility, we searched DNA sequences as follows. Nucleotide
sequences (the ¢rst V3000 bp upstream of the translation initiation
site) of each gene were obtained from LocusLink (http://www.ncbi.
nlm.nih.gov/LocusLink/) and by homology search. To screen for the
consensus p53 binding site, a computer was programmed according to
the method described by Wang et al. [18], in which no more than three
mismatches with the canonical consensus sequence were permitted,
and all decamers must contain a cytosine at position 4 and a guanine
at position 7.
2.8. Reverse transcriptase (RT)-PCR analysis
To validate the microarray data, we selected two genes (PTMA and
NUMA1) randomly from the 83 p53-related genes (Tables 2 and 3).
We then performed RT-PCR analysis of ¢ve wt-p53 HCC samples,
¢ve mt-p53 HCC samples, and four non-cancerous liver control sam-
ples. RT and PCR were performed as described previously [9,11].
PCR was performed for 24 cycles for L-actin, 27 cycles for PTMA,
and 30 cycles for NUMA1. The primers used in this study were as
follows: PTMA, 5P-GGGGAGGAAGAGGAGGAGGAA-3P (sense)
and 5P-TGGTGGAGAGCGCGTGTCATC-3P (antisense); NUMA1,
5P-GAAGCAGCCGGTGTCAGAGAG-3P (sense) and 5P-ATCTCC-
CTCTTGGCCTGGTGG-3P (antisense); and L-actin, 5P-CCAGAG-
CAAGAGAGGTAT-3P (sense) and 5P-CTGTGGTGGTGAAGCT-
GTAG-3P (antisense). The expected sizes were 318 bp, 378 bp, and
436 bp for PTMA, NUMA1, and L-actin genes, respectively. PCR
products were separated by electrophoresis on 1.5% agarose gels
and visualized under ultraviolet light after ethidium bromide staining
(Fig. 3).
2.9. Statistical analysis
Fisher’s exact test, Student’s t-test and Mann^Whitney’s U-test
were used to analyze di¡erences in clinicopathologic features between
HCCs with mt-p53 and those with wt-p53.
Table 1
Summary of clinicopathologic factors and p53 status
Sample no. Age Sex TNM stage Di¡erentiation Tumor size (cm) p53 status Codon Nucleotide change
HCV2T 49 M IIIA G2 13.5 Wild
HCV6T 61 M IIIA G2 5 Wild
HCV8T 75 M I G2 2.6 Wild
HCV10T 73 M IIIA G2 8 Wild
HCV18T 60 M II G2 3.2 Wild
HCV19T 64 M II G3 2.1 Wild
HCV21T 66 M II G3 1.8 Wild
HCV22T 70 F I G2 4.8 Wild
HCV23T 68 F IIIA G2 7.5 Wild
HCV31T 67 F I G2 10.5 Wild
HCV34T 66 M II G2 2.5 Wild
HCV35T 72 F IV G3 23 Mutant 145 CTGCCGG (LeuCArg)
HCV37T 64 M II G2 2.2 Mutant 193 CATCCGT (HisCArg)
HCV42T 58 M I G1 2.5 Wild
HCV43T 58 M IV G2 12 Mutant 244 GGCCGCC (GlyCAla)
HCV45T 73 M I G2 2.8 Wild
HCV49T 65 M IIIA G2 13 Mutant 244 GGCCGCC (GlyCAla)
HCV59T 58 F II G2 3.5 Wild
HCV60T 69 M IIIA G2 7 Mutant 244 GGCCGCC (GlyCAla)
HCV62T 74 F I G2 2.9 Wild
HCV86T 73 F I G1 1.2 Wild
HCV87T 74 M stage II G1 2.9 Wild
G1, well di¡erentiated HCC; G2, moderately di¡erentiated HCC; G3, poorly di¡erentiated HCC.
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3. Results
Missense mutations in exons 5^9 of the p53 cDNA were
detected in ¢ve of 22 tumors (23%), and p53 was intact in
the remaining 17 tumors (Fig. 1, Table 1). On the basis of
this result, the ¢ve mutant tumors and the 17 wild-type tu-
mors were classi¢ed as mt-p53 and wt-p53, respectively.
Although limited in terms of the numbers of samples, there
were no signi¢cant di¡erences in clinicopathologic features
between tumors with mt-p53 and those with wt-p53. All ¢ve
mt-p53 tumors were positive for nuclear accumulation of p53.
Four of ¢ve wt-p53 tumors tested were negative for nuclear
accumulation of p53 (data not shown). Thus, genetic abnor-
mality of p53 was consistent with nuclear accumulation of p53
as detected by immunohistochemistry.
Our supervised learning method identi¢ed 83 genes associ-
ated with p53 status from more than 6000 genes screened (Fig.
2, Tables 2 and 3). Of these 83 genes, 25 were underexpressed,
and 58 were overexpressed in mt-p53 HCCs compared with
wt-p53 HCCs. These genes have various biological functions
(Tables 2 and 3); the underexpressed genes included apopto-
sis-related genes (NUMA1, STK25), immune response-related
genes (SATB1, TNFRSF5, and CTLA4), signal transduction-
related genes (GRIN2C, TACR2, FY, and AGTRL1), and
transcription-related genes (ATF7, CTF2A1, and RING1).
The overexpressed genes included oncogenesis-related genes
(RAB1A, TPM3, and ADM), cell proliferation-related genes
(SSR1, PTMA), metastasis-related genes (LAMP1, CTSL),
and cell cycle-related genes (CCNG2, BZAP45). Our com-
puter search identi¢ed the consensus p53 binding sequence
in the 3-kb region upstream of the translation initiation site
in 18 of the 25 underexpressed genes and in 41 of the 58
overexpressed genes (Tables 2 and 3).
To validate our microarray data, we analyzed the expres-
sion levels of PTMA and NUMA1 genes in 10 representative
HCC samples (¢ve wt-p53 and 5 mt-p53) and four non-can-
cerous liver specimens by RT-PCR. Expression levels of
PTMA were markedly higher in mt-p53 HCC than in wt-
p53 HCC or non-cancerous liver (Fig. 3). Expression levels
of NUMA1 were repressed in mt-p53 HCC compared with
non-cancerous liver, with the exception of one sample
(HCV43T in Fig. 3). In contrast, expression levels of
NUMA1 were higher in all samples of wt-p53 HCC than in
those of non-cancerous liver. Thus, expression patterns by
microarray were consistent with those by RT-PCR.
4. Discussion
Patients with HCV-related HCC have various backgrounds
and divergent clinical courses, resulting in much heterogeneity
between tumor samples [11]. Unlike in vitro studies with cell
lines, in analyzing transcriptomes in human cancer tissues, it
is crucial to take interpatient heterogeneity into consideration.
With this concept in mind, we used the Fisher ratio and the
random permutation test [9,11] to identify molecular signa-
tures related to p53 status.
Table 2
Twenty-¢ve genes underexpressed in HCCs with mt-p53 compared with those with wt-p53
Fisher ratio Accession number Abbreviation Locus p53 binding sitea Function
3.85 X13973 RNH 11p15.5 3710 to 3687, 3697 to 3675 Inhibition of angiogenesis
3.69 U05659 HSD17B3 9q22 32673 to 32647 Metabolism
3.60 M97287 SATB1 3p23 31324 to 31301 Immune response
3.29 X60592 TNFRSF5 20q12^q13.2 31133 to 31106, 3318 to 3297,
3318 to 3287
Immune response/cell cycle
arrest
3.15 M37457 ATP1A3 19q13.2 NDb Molecular transport
3.11 L76224 GRIN2C 17q25 3927 to 3894 Signal transduction
3.00 Y11897 CHIC1 Xq13^q21 absent Unknown
2.98 M37245 CTLA4 2q33 32742 to 32719, 32413 to 32387 Immune response
2.97 M60284 TACR2 10q11^q21 32980 to 32958, 32793 to 32760,
3871 to 3842, 3716 to 3683
Signal transduction
2.78 X12433 ABHD2 15q26 32833 to 32800, 32422 to 32398,
31433 to 31403
Unknown
2.78 Y08265 CHERP 19p13.1 32275 to 32255 Neurogenesis
2.53 HG2238-HT2321 NUMA1 11q13 32813 to 32793, 32803 to 32771 Apoptosis
2.51 Z14000 RING1 6p21.3 absent Transcription
2.45 M37755 PSG1 19q13.2 absent Immune response
2.44 X85785 FY 1q21^q22 absent Signal transduction
2.37 L10338 SCN1B 19q13.1 31580 to 31557 Molecular transport
2.36 U03642 AGTRL1 11q12 32388 to 32364, 31987 to 31958,
3727 to 3700
Signal transduction
2.31 HG2566-HT4867 MAPT 17q21.1 32874 to 32854, 31379 to 31350 Cell motility/microtubule
assembly
2.28 L18983 PTPRN 2q35^q36.1 3585 to 3563, 3521 to 3499 Miscellaneous
2.27 X54870 D12S2489E 12p13.2^p12.3 32694 to 32664 Immune response
2.24 X99325 STK25 2q37.3 32667 to 32643, 32667 to 32635 Apoptosis
2.24 D87465 KIAA0275 10pter^q25.3 32137 to 32116 Unknown
2.17 X52943 ATF7 12q13 absent Transcription
2.14 U24056 KCNJ4 22q13.1 NDb Molecular transport
2.13 HG3162-HT3339 GTF2A1 14q31.1 31470 to 31440 Transcription
Accession numbers were obtained from PubMed (http://www3.nibi.nlm.nih.gov/PubMed/) or TIGR (http://www.tigr.org/tdb/hgi/searching/re-
ports.html) databases.
Abbreviations were used based on the data from LocusLink (http://www.nibi.nlm.nih.gov/LocusLink/).
aDNA sequence was searched for the ¢rst 3000 bp upstream of the translation initiation site. Number corresponds to the upstream nucleotide
of the translation initiation site.
bNot determined.
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Table 3
Fifty-eight genes overexpressed in HCCs with mt-p53 compared with those with wt-p53
Fisher ratio Accession number Abbreviation Locus p53 binding sitea Function
8.75 M28209 RAB1A 2p14 31692 to 31662, 3722 to 3702 Oncogenesis/Signal
transduction
6.75 U81006 TM9SF2 13q32.3 3212 to 3183, 3125 to 3101 Endosomal protein
6.61 X81003 PPP1R11 6p21.3 31572 to 31548 Hemochromatosis
candidate gene
6.28 X76228 ATP6V1E1 22q11.1 absent Molecular transport
6.25 U02680 PTK9 12p11.22 31850 to 31823, 3305 to 3283 Signal transduction
5.54 D87446 RW1 2q11.1 32949 to 32927, 3889 to 3867, 3889
to 3863, 3889 to 3862, 3876^844
Unknown
5.12 HG2755-HT2862 PLS3 Xq24 absent Signal transduction
4.23 M19311 CALM2 2p21 3401 to 3377 Signal transduction
4.23 Z12830 SSR1 6p23 32086 to 32064, 32073 to 32053,
32073 to 32048, 31259 to 31239
Cell proliferation
4.13 L24804 TEBP 12q12 31189 to 31168 Signal transduction
3.97 U47414 CCNG2 4q13.3 31713 to 31693 Cell cycle
3.83 X68194 SYPL 7q11.23 3467 to 3448 Molecular transport
3.72 D87684 UBXD2 2q14.3 32115 to 32096 Unknown
3.67 M23294 HEXB 5q13 31619 to 31597, 31231 to 31203 Metabolism
3.66 X92098 RNP24 12q24.31 absent Molecular transport
3.64 U62136 UBE2V2 8q11.1 absent Proteolysis/peptidolysis
3.61 D14658 KIAA0102 11q13.3 absent Unknown
3.50 U73824 EIF4G2 11p15 absent Translational modi¢cation
3.47 AF002020 NPC1 18q11^q12 32712 to 32682, 32711 to 32682 Molecular transport
3.47 U14603 PTP4A2 1p35 31254 to 31235 Signal transduction
3.43 D13630 BZW1 2q33 31530 to 31510 Cell cycle
3.40 U86782 POH1 2q24.3 31478 to 31455 Proteolysis/peptidolysis
3.40 X90872 HSGP25L2G 5q35.3 absent Molecular transport
3.32 M28713 DIA1 22q13.2-q13.31 absent Energy pathway
3.16 L38961 ITM1 11q23.3 32769 to 32747, 32395 to 32372,
32381 to 32358, 32116 to 32086,
32095 to 32063, 31367 to 31341
Transmembrane protein
3.09 M26708 PTMA 2q35^q36 31738 to 31715, 31352 to 31320 Cell proliferation
3.07 U41766 ADAM9 8p11.21 3412 to 3388 Cell motility/cell adhesion
3.03 HG2463-HT2559 CDC42 1p36.1 32846 to 32826, 31531 to 31501 Miscellaneous
2.99 HG4297-HT4567 PC4 5p13.3 31919 to 31898, 31011 to 3984 Transcription
2.97 M33521 BAT3 6p21.3 32150 to 32128 Stress response
2.91 Z48042 M11S1 11p13 3639 to 3609 Plasma membrane
2.88 M36341 ARF4 3p21.2^p21.1 absent Signal transduction/
metabolism
2.80 U93205 CLIC1 6p22.1^p21.2 32130 to 32104 Molecular transport
2.76 HG3514-HT3708 TPM3 1q21.2 32884 to 32863, 32808 to 32784,
32404 to 32382
Oncogenesis
2.73 M75715 ETF1 5q31.1 32310 to 32291, 32300 to 32281,
31281 to 31260, 3388 to 3365
Translation
2.68 J03263 LAMP1 13q34 31258 to 31239 Metastasis
2.67 D49489 P5 2p25.1 31802 to 31779 Metabolism
2.66 M38591 S100A10 1q21 32197 to 32177 Cell proliferation
2.61 U18009 VATI 17q21 absent Molecular transport
2.60 X56468 YWHAQ 2p25.1 absent Signal transduction/cell
cycle
2.57 S65738 DSTN 20p11.23 31971 to 31946, 31890 to 31869,
31562 to 31537
Cell structure
2.55 D14874 ADM 11p15.4 31236 to 31204, 3301 to 3269 Oncogenesis
2.50 D80005 C9orf10 9q22.31 3606 to 3580, 3200 to 3175 Unknown
2.43 Y00282 RPN2 20q12^q13.1 3647 to 3628 Metabolism
2.40 D78577 YWHAH 22q12.3 31637 to 31613, 31637 to 31612,
31588 to 31560, 31038 to 31017,
3937 to 3917, 3937 to 3906, 3926
to 3906
Signal transduction
2.38 M64992 PSMA1 11p15.1 3534 to 3513 Proteolysis/peptidolysis
2.37 U02556 TCTE1L Xp21 absent Unknown
2.34 V00572 PGK1 Xq13 31901 to 31877, 31886 to 31867 Signal transduction
2.34 AB000468 RNF4 4p16.3 32876 to 32854, 32729 to 32704,
3602 to 3572
Transcription
2.30 X57346 YWHAB 20q13.1 31127 to 31100 Signal transduction
2.27 U26312 CBX3 7p15.2 NDb DNA binding protein
2.26 X74104 SSR2 1q21-q23 absent Signal transduction
2.25 D00017 ANXA2 15q21^q22 32356 to 32329 Cell proliferation
2.23 D86960 KIAA0205 1p36.13^q42.3 absent Unknown
2.22 U82130 TSG101 11p15 3808 to 3785, 3498 to 3466 Oncogenesis
2.18 X12451 CTSL 9q21^q22 absent Proteolysis/peptidolysis
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Table 3 (Continued).
Fisher ratio Accession number Abbreviation Locus p53 binding sitea Function
2.18 U62389 IDH1 2q33.3 absent Energy pathway
2.14 J04611 G22P1 22q13.2^q13.31 31513 to 31482 DNA repair
Accession numbers were obtained from PubMed (http://www3.nibi.nlm.nih.gov/PubMed/) or TIGR (http://www.tigr.org/tdb/hgi/searching/re-
ports.html) databases.
Abbreviations were used based on the data from LocusLink (http://www.nibi.nlm.nih.gov/LocusLink/).
aDNA sequence was searched for the ¢rst 3000 bp upstream of the translation initiation site. Number corresponds to the upstream nucleotide
of the translation initiation site.
bNot determined.
Fig. 1. p53 status (A,B) and p53 immunostaining (C,D) in representative cases. A,B: Sequence chromatographs of codon 244 of HCV2T and
HCV60T, respectively. HCV2T carries wild-type p53, whereas HCV60T shows a missense mutation of Gly (GGC) to Ala (GCC) at codon 244.
C: Lack of p53 staining in HCV2T (40U). No cancer cells are stained. D: p53 staining in a tissue section from HCV60T (100U). Most of the
cancer cell nuclei stain with the anti-p53 antibody (DO-7). Note that normal hepatocytes show no p53 staining. T, primary tumor; N, non-tu-
morous liver.
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The most striking ¢nding of our study is that HCV-infected
HCCs with wt-p53 and those with mt-p53 di¡er signi¢cantly
in their gene expression patterns. Our gene selection revealed
that cell cycle-related genes (CCNG2, BZAP45) and cell pro-
liferation-related genes (SSR1, ANXA2, S100A10, and
PTMA) were overexpressed in mt-p53 tumors compared
with wt-p53 tumors. On the basis of altered levels of these
genes, it is reasonable to assume that mt-p53 tumors have
higher malignant potentials than do wt-p53 tumors. This con-
cept is supported by previous reports that p53 mutations con-
stitute an unfavorable prognostic factor related to recurrence
in HCC [19,20]. Our present results with CCNG2 and PTMA
are consistent with those of previous reports [21,22]. CCNG2
encodes human cyclin G2. Bates et al. [21] reported that
Fig. 2. Gene expression pro¢les linked to p53 status in HCC. Samples are listed horizontally. Upper panel, 25 genes underexpressed in tumors
with mt-p53 compared with wt-p53. Lower panel, 58 genes overexpressed in mt-p53 tumors compared to wt-p53 tumors. Genes are ranked in
decreasing order of Fisher ratio (see Section 2) and listed according to accession number. The accession numbers were obtained from the
PubMed (http://www3.ncbi.nlm.nih.gov/PubMed/) or TIGR (http://www.tigr.org/tdb/hgi/searching/reports.html) databases.
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although induction of cyclin G1 expression is p53-dependent,
activation of cyclin G2 expression by DNA-damaging agents
occurs in the absence of p53. Transcription of PTMA is di-
rectly repressed by p53 [22], indicating that it is relatively
overexpressed in mt-p53 tumors. Interestingly, it was reported
that PTMA is overexpressed in HCC [23]. Our present ¢nding
that PTMA is predominantly expressed in mt-p53 HCC sug-
gests that PTMA in mt-p53 HCC may be a molecular target
for cancer therapy.
Unexpectedly, our computer search detected the consensus
p53 binding sequence in the 3-kb region upstream of the
translation initiation site in both overexpressed and underex-
pressed genes. This result suggests that in human cancer tis-
sues the p53-associated transcription system possesses more
complicated pathways. This concept is supported by our result
that, with the exceptions of CCNG2 and PTMA, most of the
83 genes listed here are distinct from those p53-related genes
identi¢ed previously [22]. Additionally, in our in vivo study, it
is unclear whether wt-p53 is activated in tumor tissues. Fur-
ther studies are required to clarify whether these genes are
directly regulated by wt-p53.
Many immune system-related genes, including SATB1,
TNFRSF5, and CTLA4, were underexpressed in mt-p53 tu-
mors. Because we did not perform laser capture microdissec-
tion (LCM), it is possible that the cancer samples tested con-
tained stromal cells at concentrations of 5^10%. It is also
important to consider that the expression patterns of the 83
genes identi¢ed here did not necessarily originate from the
cancer cells themselves. Recently, we found that vimentin is
produced preferentially by stromal cells within cancer tissues,
and downregulation of vimentin expression is associated with
early intrahepatic recurrence of HCC [10]. This is a clear
example of identi¢cation of a gene derived from stromal cells,
suggesting that gene analyses following LCM may fail to pro-
vide such an important ¢nding. Mouta Carreira et al. ob-
served the withdrawal of intratumor lymphatics in HCC tissue
compared with non-tumorous liver tissue [24]. The decreased
levels of immune system-related genes observed in mt-p53
HCCs in the present study may re£ect the withdrawal of stro-
mal cells within cancer tissues or downregulation of the im-
mune system reaction against cancer cells in parallel with
tumor progression. Further studies are needed to clarify
whether these genes are derived from cancer cells or stromal
cells and whether the consensus sequences identi¢ed here
function as regulators of p53-dependent transcription.
Our present data provide unique evidence that PTP4A2 is
overexpressed and ATF7 is underexpressed in mt-p53 tumors.
PTP4A2 (PRL-1) encodes a nuclear protein-tyrosine phospha-
tase that is an immediate-early gene in liver regeneration and
is positively associated with growth, including fetal and neo-
plastic hepatic growth [25]. It is, therefore, reasonable to as-
sume that upregulation of PTP4A2 promotes cancer cell pro-
liferation in mt-p53 HCC. Because a recent study revealed
that ATF7 interacts directly with PTP4A2 [26], these two
genes are likely to have biologic actions in response to p53
status. Our data also show that annexin II (ANXA2) and
S100A10, which are involved in cell proliferation, are overex-
pressed in mt-p53 tumors. Interestingly, S100A10 is an annex-
in II ligand, suggesting that the two genes are closely related
to the growth of HCV-related HCC with mt-p53. Thus, we
expect that our data will aid in understanding the role of p53
in the pathogenesis of HCV-related HCC.
In conclusion, our present data show that HCV-infected
HCCs with wt-p53 and those with mt-p53 di¡er signi¢cantly
in their gene expression patterns. Because p53 has attracted a
great deal of attention as a molecular target for cancer gene
therapy [27], our present data may serve as a useful tool for
predicting the e⁄cacy of p53-based therapies.
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